These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 24342031)

  • 41. Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma.
    Nandha R
    J Postgrad Med; 2012; 58(3):203-6. PubMed ID: 23023354
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CYP17 inhibitors improve the prognosis of metastatic castration-resistant prostate cancer patients: A meta-analysis of published trials.
    Cao Q; Bai P; Shi D; Liao J; Shi H; Xing Y; Chen K; Zhang X
    J Cancer Res Ther; 2020 Sep; 16(5):990-1001. PubMed ID: 33004739
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.
    Azad AA; Leibowitz-Amit R; Eigl BJ; Lester R; Wells JC; Murray RN; Kollmannsberger C; Heng DY; Joshua AM; Chi KN
    Prostate; 2014 Nov; 74(15):1544-50. PubMed ID: 25175831
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer.
    Matsubara N; Uemura H; Fukui I; Niwakawa M; Yamaguchi A; Iizuka K; Akaza H
    Cancer Sci; 2014 Oct; 105(10):1313-20. PubMed ID: 25117615
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer.
    McKay RR; Werner L; Fiorillo M; Nakabayashi M; Kantoff PW; Taplin ME
    Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):398-405. PubMed ID: 27502737
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone.
    Leibowitz-Amit R; Alimohamed N; Vera-Badillo FE; Seah JA; Templeton AJ; Knox JJ; Tannock IF; Sridhar SS; Joshua AM
    Prostate; 2014 Oct; 74(14):1462-4. PubMed ID: 25111736
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Study of cases of abiraterone discontinuation due to toxicity in pre-chemotherapy after 1 year's experience.
    Ramudo-Cela L; Balea-Filgueiras J; Vizoso-Hermida JR; Martín-Herranz I
    J Oncol Pharm Pract; 2017 Dec; 23(8):615-619. PubMed ID: 27753628
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary.
    Kluetz PG; Ning YM; Maher VE; Zhang L; Tang S; Ghosh D; Aziz R; Palmby T; Pfuma E; Zirkelbach JF; Mehrotra N; Tilley A; Sridhara R; Ibrahim A; Justice R; Pazdur R
    Clin Cancer Res; 2013 Dec; 19(24):6650-6. PubMed ID: 24150234
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
    Koroki Y; Imanaka K; Yasuda Y; Harada S; Fujino A
    Jpn J Clin Oncol; 2021 Aug; 51(9):1452-1461. PubMed ID: 34050660
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.
    Rehman Y; Rosenberg JE
    Drug Des Devel Ther; 2012; 6():13-8. PubMed ID: 22291466
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.
    Fizazi K; Scher HI; Molina A; Logothetis CJ; Chi KN; Jones RJ; Staffurth JN; North S; Vogelzang NJ; Saad F; Mainwaring P; Harland S; Goodman OB; Sternberg CN; Li JH; Kheoh T; Haqq CM; de Bono JS;
    Lancet Oncol; 2012 Oct; 13(10):983-92. PubMed ID: 22995653
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CYP17A1 inhibitors in castration-resistant prostate cancer.
    Gomez L; Kovac JR; Lamb DJ
    Steroids; 2015 Mar; 95():80-7. PubMed ID: 25560485
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influence of Statins on Survival Outcome in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone Acetate.
    Boegemann M; Schlack K; Fischer AK; Gerß J; Steinestel J; Semjonow A; Schrader AJ; Krabbe LM
    PLoS One; 2016; 11(9):e0161959. PubMed ID: 27583544
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer.
    Stover JT; Moore RA; Davis K; Harrison MR; Armstrong AJ
    Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):161-6. PubMed ID: 25777155
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.
    Bahl A; Masson S; Birtle A; Chowdhury S; de Bono J
    Cancer Treat Rev; 2014 Feb; 40(1):170-7. PubMed ID: 23958310
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: a prospective evaluation.
    Prati V; Ruatta F; Aversa C; Gernone A; Galizia D; Bonzano A; Torino S; Nuzzolese I; Marandino L; Aglietta M; Ortega C
    Future Oncol; 2018 Feb; 14(5):443-448. PubMed ID: 29318908
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Abiraterone in metastatic castration-resistant prostate cancer: Efficacy and safety in unselected patients.
    Marret G; Doucet L; Hennequin C; Fizazi K; Culine S
    Cancer Treat Res Commun; 2018; 17():37-42. PubMed ID: 30347333
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors.
    Procopio G; Grassi P; Testa I; Verzoni E; Torri V; Salvioni R; Valdagni R; de Braud F
    Am J Clin Oncol; 2015 Oct; 38(5):479-82. PubMed ID: 24064757
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer.
    Francini E; Fiaschi AI; Petrioli R; Francini F; Bianco V; Perrella A; Paganini G; Laera L; Roviello G
    Anticancer Drugs; 2014 Apr; 25(4):472-7. PubMed ID: 24394473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.